Gautam Borthakur
M.D. Anderson Cancer Center · The University of Texas MD Anderson Cancer Centre · MD Anderson Cancer Center Houston, TX 77030
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
24
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
197
PubMed author-name match
Trials
Studies that name Gautam Borthakur as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:09 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07053020 · A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · not yet recruiting · Acute Myeloid Leukemia (AML) · principal investigator
- Ph1/Ph2NCT06548230 · A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)M.D. Anderson Cancer Center · recruiting · Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML) · principal investigator
- Ph1/Ph2NCT06113289 · A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid LeukemiaM.D. Anderson Cancer Center · withdrawn · Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT04730258 · A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLTreadwell Therapeutics, Inc · active not recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia · principal investigator
- Ph1NCT04017546 · CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDSCyclacel Pharmaceuticals, Inc. · completed · AML, MDS · principal investigator
- Ph1NCT03884829 · A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDSCyclacel Pharmaceuticals, Inc. · terminated · AML, Adult, Myelodysplastic Syndromes, ALL, Adult · principal investigator
- Ph2NCT03207542 · Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · withdrawn · Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic · principal investigator
- Ph2NCT03067571 · Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · terminated · High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1NCT02649764 · Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent High Risk Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT02418000 · A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras MutationsSpirita Oncology, LLC · terminated · AML, MDS, CMML · study chair
- Ph1/Ph2NCT02392572 · ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · terminated · Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT01828346 · Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine TherapyTetraLogic Pharmaceuticals · completed · Myelodysplastic Syndrome · principal investigator
- Ph2NCT01692197 · E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic SyndromesM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph2/Ph3NCT01428635 · Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase TherapyM.D. Anderson Cancer Center · completed · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
- Ph2NCT01222195 · Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT01029509 · Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic SyndromesM.D. Anderson Cancer Center · terminated · Leukemia · study chair
- Ph2NCT00968071 · Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome · study chair
- Ph2NCT00960726 · NOV-002 in Myelodysplastic Syndrome (MDS)M.D. Anderson Cancer Center · withdrawn · Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT00905034 · Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) SalvageM.D. Anderson Cancer Center · completed · Leukemia, Lymphocytic, Acute · principal investigator
- Ph2NCT00882102 · Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)M.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph1NCT00867230 · FTS Study in Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome, Leukemia · principal investigator
- Ph2NCT00520468 · Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDSM.D. Anderson Cancer Center · completed · Myelodysplastic Syndrome · principal investigator
- Ph1/Ph2NCT00480987 · Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)M.D. Anderson Cancer Center · terminated · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia · principal investigator
- Ph2NCT00360672 · Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:09 UTC. The ranking covers the 200 most relevant of 197 PubMed records, and a shared surname and initials can bring in a namesake. All 197 on PubMed
- Ibrutinib and Venetoclax for First-Line Treatment of CLL.N Engl J Med · 2019426 citationsRCR 15.0
- Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.J Clin Oncol · 2009332 citationsRCR 7.7
- 328 citationsRCR 8.7
- Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.J Clin Oncol · 2010311 citationsRCR 7.4
- 307 citationsRCR 8.2
- Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.J Clin Oncol · 2021297 citationsRCR 16.3
- Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.J Clin Oncol · 2007295 citationsRCR 6.8
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- 279 citationsRCR 6.3
- 226 citationsRCR 8.0